Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy Pharmaceutical Business ReviewThe approval covers both adult and paediatric patients aged eight years and above.Rare DiseaseRead full story pharminent August 20, 2026 (Last updated: August 23, 2026) Pharmaceutical Business Review The approval covers both adult and paediatric patients aged eight years and above. Rare Disease Read full story Post navigation Previous: Moderna and Merck’s Personalized Melanoma Vaccine Scores Historic Phase 3 WinNext: Regeneron wins FDA approval to challenge Ipsen for rare bone disease market Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026 Regulatory Trump nominates policy aide Overton to lead FDA pharminent August 19, 2026
